Vetter expands its footprint in Asia Pacific region

Nov 9, 2017

Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the official opening of a new branch office in South Korea. The new office in Songdo is located within the biologics cluster which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.   Strengthening its global footprint in the Asia Pacific (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an office in Tokyo in 2015. Although the ...

Read More

Gerresheimer Medical Systems at Compamed 2017: From usability engineering through to a CE-marked product

Nov 9, 2017

As a full-service provider, Gerresheimer Medical Systems will be attending the Compamed trade fair in Düsseldorf from November 13 to 16, with an exhibit at booth P33 in Hall 8A of the grounds.  “Medical technology systems are subject to increasingly stringent requirements in terms of material, design, function, and quality,” says Peter Wallrabe, Global Director Product Design Medical Systems at Gerresheimer. “We support our customers from the initial product idea through to further product development.” This applies to small-scale production too, where it is possible to supply development and clinical samples at any point in a project involving anything up ...

Read More

Sanofi and Principia agree to develop MS drug candidate

Nov 9, 2017

Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling. PRN2246 is currently in clinical development. “Our agreement with Principia is an example of Sanofi’s strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases,” says Rita Balice-Gordon, PhD, Global Head ...

Read More

IDBS takes Bioprocess Execution Solution to the Cloud

Nov 9, 2017

IDBS announces the release of its latest Bioprocess Execution (BPES) informatics solution. Leveraging the IDBS E-WorkBook Cloud platform, the solution provides an out-of-the-box capability that enables cell-line development, fermentation scale-up and purification, and clinical supply workflows to be executed in a single, unified, and compliant informatics and data management environment.   Dr. Paul Denny-Gouldson, Vice President, Strategic Solutions, IDBS said, “the latest incarnation of BPES takes advantage of the latest technology platform that IDBS offers – simplifying scientists’ laboratory-based working, whilst ensuring the highest level of compliance and regulatory requirements. Clients can also simplify their lab informatics environments and take ...

Read More

Immuno-oncology CRO secures Macrophage Pharma agreement

Nov 9, 2017

Aquila BioMedical Ltd., an innovative preclinical contract research organisation (CRO) now part of Concept Life Sciences group, has secured an extended agreement with UK-based biotech firm Macrophage Pharma Ltd. to support its preclinical immuno-oncology programmes.   Macrophage Pharma’s Esterase Sensitive Motif™ (ESM™) technology enables delivery of novel, small molecule drug candidates to tumour associated macrophages in a selective manner to reverse immunosuppression established in the tumour microenvironment, and could progress to provide a next-generation immunotherapy with broad utility in oncology.   Macrophage Pharma’s immuno-oncology programme with Aquila will incorporate a combination of in vitro, in vivo and ex vivo analyses. This will generate data to enable ...

Read More